Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan 26:10:7-16.
doi: 10.2147/RRU.S125635. eCollection 2018.

Urothelial carcinoma: the evolving landscape of immunotherapy for patients with advanced disease

Brian Dietrich  1 , Sandy Srinivas  2
Affiliations
Review

Urothelial carcinoma: the evolving landscape of immunotherapy for patients with advanced disease

Brian Dietrich et al. Res Rep Urol. .

Abstract

Urothelial carcinoma is the sixth most common malignancy in the US. While most patients present with non-muscle-invasive disease, many will develop recurrent disease including some progressing to muscle invasive metastatic cancer. Treatment outcomes have remained poor and stagnant for those with more advanced illness, with typical 5-year survival rates in the range of ≤15%. While first-line, platinum-based chemotherapy remains the current standard for those eligible, the recent incorporation of checkpoint inhibitors into the management of advanced bladder cancer has resulted in an expansion of treatment options for a difficult-to-treat disease. This review will discuss the historic standard treatment options, followed by the more recent evolving role immune therapy has in the management of bladder cancer.

Keywords: bladder cancer; checkpoint inhibitor; immunotherapy; urothelial.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. - PubMed
    1. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Bladder cancer, version 5. 2017. [Accessed December 13, 2017]. Available from: NCCN.org.
    1. Park JC, Citrin DE, Agarwal PK, Apolo AB. Multimodal management of muscle invasive bladder cancer. Curr Probl Cancer. 2014;38(3):80–108. - PMC - PubMed
    1. Survival rates for bladder cancer. American Cancer Society; [Accessed May 23, 2016]. Available from: http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-....
    1. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J Clin. 2012;62(5):309–355. - PMC - PubMed

LinkOut - more resources